Clinical trial • Phase IV • Musculoskeletal|Other
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Temporomandibular disorder
Phase IV trial of CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Temporomandibular disorder. 1 participants.
Overview
- Trial Therapeutic Area
- Musculoskeletal|Other
- Trial Disease
- Temporomandibular disorder
- Trial Stage
- Phase IV
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 26-10-2023
- First CTIS Authorization Date
- 05-02-2024
Trial design
Phase IV trial in Sweden.
- Target Sample Size
- 1
Eligibility
Recruits 1 No vulnerable populations selected. Only adults aged 18-45 are eligible. No assent/consent handling details are provided. Exclusion includes "difficulties understanding the Swedish language.".
- Pregnancy Exclusion
- 9) pregnancy or nursing
- Vulnerable Population
- No vulnerable populations selected. Only adults aged 18-45 are eligible. No assent/consent handling details are provided. Exclusion includes "difficulties understanding the Swedish language."
Inclusion criteria
- {"criterion_text":"- a) Female gender\n- b) age 18-45 years\n- c) diagnos of myalgia, myofacial pain or myofascial pain with refered pain according to DC/TMD\n- d) an average pain due to NRS ≥ 3 for more than three months\n- e) treatment for orofacial pain > three months ago.\n- f) with adequate contraceptives and a negative pregnancy test. Patients will still be included even if they have one or more co-diagnoses 1) Discdisplacement with or without reduction according to DC/TMD 2) degenerative joint disease 3) arthralgia"}
Exclusion criteria
- {"criterion_text":"- 1) treatment with BTX during the last six months\n- 2) treatment for orofacial pain within the last 3 months.\n- 3) systemic inflammatory diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis)\n- 4) fibromyalgia\n- 5) neuropathic pain\n- 6) neurologic disease (myastenia gravis)\n- 7) pain of dental origin\n- 8) use of muscle relaxants or aminoglycoside antibiotics\n- 9) pregnancy or nursing\n- 10) hypersensitivity to BTX\n- 11) neuropsychiatric conditions.\n- 12) difficulties understanding the Swedish language.\n- 13) Trauma to head, neck or face, including orthognatic surgery"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Changes in pain and if the dose matters for pain relief is the primary outcome.","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- Changes in quality of life according to OHIP. Treatment outcome in sub-groups of myogenous TMD. Maximum jaw opening with and without pain between doses and subgroups. The patient´s changes psychosocially, how the jawfunction is affected according to changes in Axis II and changes in PPT.","definition_or_measurement_approach":""}
Recruitment
- Planned Sample Size
- 1
- Recruitment Window Months
- 23
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 1
Sweden
- Earliest CTIS Part Ii Submission Date
- 17-01-2024
- Latest Decision Or Authorization Date
- 05-02-2024
- Processing Time Days
- 19
- Number Of Sites
- 1
- Number Of Participants
- 1
Sites
- Site Name
- Region Stockholm Folktandvarden
- Department Name
- Avdelningen för bettfysiologi
- Contact Person Name
- Veronica de Flon
- Contact Person Email
- veronica.deflon@regionstockholm.se
- Number Of Participants
- 1
Sponsor
Primary sponsor
- Full Name
- Region Stockholm Folktandvarden
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
- Active Substance
- CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
- Modality
- Peptide/protein/enzyme
- Routes Of Administration
- DENTAL USE
- Route
- DENTAL USE
- Maximum Dose
- 100 U unit(s)
Related trials
Other published trials that may interest you.